Investigation of anxiety, depression and quality of life levels in migraine patients seeking surgical treatment

Objective: Pharmacotherapeutics have been used as a primary agent in migraine treatment. The detection of triggers that exacerbated migraine in recent years and the effectiveness of the surgical interventions applied in this area have been demonstrated. The aim of this study was to investigate the depression, anxiety and quality of life in migraine patients seeking surgical treatment by comparing them with migraine and non-migraine group. Method: A total of 105 participants were included in the study: 35 migraine patients seeking surgical treatment, 35 migraine patients not-seeking surgical treatment, and 35 healthy controls without migraine. Participants filled out forms consisting of Beck Depression Scale, Beck Anxiety Scale, SF-36 Quality of Life Scale and sociodemographic data form. One-way analysis of variance and Post-hoc Bonferroni test were used to assess intergroup depression, anxiety and quality of life scores. Results:Anxiety (F=6,02; p=0,003), and depression (F=10,72; p<0,001) scores were higher in migraine patients seeking surgical treatment group. In the quality of life subscales, bodily pain scores were higher (F=13,09; p<0,001); role-physical (F=14,72; p=0,003) and role-emotional (F=6,11; p=0,003) scores were found to be lower than the other groups. Discussion: Surgical treatment seeking behavior in migraine patients is associated with more severe anxiety and depression and worse quality of life. Psychiatric evaluation of migraine patients seeking surgical treatment may be important in detecting psychiatric disorders at the diagnostic level and in increasing the quality of life of patients

Do chronotype differences and night eating syndrome affect dental health?

Objective Our aim in this study was to examine the effect of chronotype differences and night eating syndrome on dental health parameters such as the decay-missing-filled teeth (DMFT) index, the severity of the periodontal disease and the number of endodontically treated teeth in patients admitted to the dental clinic. Methods The participants, 210 patients, filled out a package of psychological tools, including the Morningness-Eveningness Questionnaire (MEQ), the Night Eating Questionnaire (NEQ) and the Insomnia Severity Index (ISI). Afterwards, the DMFT index scores, the severity of the periodontal disease and the number of endodontically treated teeth of patients were recorded simultaneously with a routine dental examination. Results Findings show that the ISI and NEQ scores were significantly higher in the evening-type individuals (E-types) than in the morning-type individuals, and there was no significant difference between the chronotypes in terms of the number of endodontically treated teeth and the DMFT scores. In ordinal regression analyses, not brushing teeth (OR 7.94, CI 6.40-9.85), increased number of decayed teeth (OR 1.16, CI 1.13-1.19) and decreased MEQ scores (OR 0.95, CI 0.94-0.95) were statistically significant predictors for periodontal disease. Conclusion Although there was no correlation between chronotype differences and the DMFT index, and the number of endodontically treated teeth, E-types had a higher risk of periodontal disease severity

The use of buprenorphine plus naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports

Introduction: Neonatal opioid withdrawal syndrome occurs after exposure during pregnancies of mothers with an opioid use disorder. If non-pharmacological treatment is insufficient, pharmacological options are preferred, but a common treatment guideline has not yet been determined. Sublingual buprenorphine tablet is more prominent in the treatment. Since oral alternatives are not available in many clinics, as in our unit, parenteral morphine is still the drug of the first choice. In this paper, we reported that two babies with neonatal opioid withdrawal syndrome were successfully treated with a buprenorphine/naloxone combination, which was not previously shown in the literature. Cases: We followed two babies whose mothers had an opioid use disorder during their pregnancies. The modified Finnegan scoring scale was used for the assessment of the babies. Both infants developed persistent seizures with resistant withdrawal signs. An effective parenteral route could not be provided due to hemodynamic instability. Thus, IV morphine could not be used. Due to the lack of oral treatment alternatives, first, we tried phenobarbital up to 40 mg/kg orally. Afterward, we used buprenorphine/naloxone combined tablet sublingually, which has not been used in children before. Detailed written consent was obtained from the parents for the emergency use of this drug in advance. Shortly after this treatment, the seizures and withdrawal signs were controlled. There were no adverse effects and babies were discharged fully recovered. Conclusion: Sublingual Buprenorphine 2 mg + Naloxone 0.5 mg (4:1) tablet could be used efficiently and without side effects to treat neonatal opioid withdrawal syndrome